AAPG
Ascentage Pharma Group InternationalNASDAQHealthcare$27.32+3.96%ClosedMarket Cap: $2.54B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
13.18
P/S
30.88
EV/EBITDA
-15.32
DCF Value
$-80.59
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.1%
Operating Margin
-210.4%
Net Margin
-216.7%
ROE
-123.6%
ROA
-31.0%
ROIC
-33.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $334.1M | 79.4% | $-640.9M | $-640.0M | $-6.92 | — |
| FY 2025 | $558.5M | 76.4% | $-1.18B | $-1.21B | $-13.56 | — |
| Q2 2025 | $233.7M | 90.7% | $-554.0M | $-590.8M | $-6.92 | — |
| Q4 2024 | $156.9M | 91.1% | $-566.8M | $-568.4M | $-7.28 | — |
| FY 2024 | $980.6M | 97.0% | $-369.7M | $-405.4M | $-5.36 | — |
| Q2 2024 | $823.7M | 98.2% | $188.0M | $163.0M | $2.20 | — |
| Q4 2023 | $79.3M | 84.4% | $-532.1M | $-523.3M | $-7.20 | — |
| FY 2023 | $222.0M | 86.2% | $-872.6M | $-925.6M | $-52.48 | — |
| Q2 2023 | $142.7M | 87.3% | $-340.6M | $-402.4M | $-45.28 | — |
| Q4 2022 | $104.9M | 89.5% | $-424.9M | $-441.5M | $-26.80 | — |
| FY 2022 | $209.7M | 89.5% | $-849.8M | $-882.9M | $-53.60 | — |
| Q2 2022 | $104.9M | 89.5% | $-424.9M | $-441.5M | $-26.80 | — |